Search

Search Constraints

You searched for: Author/Creator Akoojee, Nazim

Search Results

1. Poor quality of life and incomplete self-reported adherence predict second-line ART virological failure in resource-limited settings. Issue 10 (3rd October 2021)

2. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. Issue 9 (September 2022)

3. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. Issue 9 (September 2022)